Calithera Biosciences, Inc. (CALA)
OTCMKTS: CALA · Delayed Price · USD
0.0200
-0.0090 (-31.03%)
Apr 24, 2024, 1:00 PM EDT - Market closed
Company Description
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023.
Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business.
Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Calithera Biosciences, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Oct 2, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Ms. Stephanie Wong |
Contact Details
Address: 343 Oyster Point Blvd #200 South San Francisco, California 94080 United States | |
| Phone | 650-870-1000 |
| Website | calithera.com |
Stock Details
| Ticker Symbol | CALA |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001496671 |
| CUSIP Number | 13089P101 |
| ISIN Number | US13089P5070 |
| Employer ID | 27-2366329 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephanie Wong | Chief Financial Officer and Secretary |
| Dr. Christopher J. Molineaux Ph.D. | Senior Vice President of Development |
| Frank Parlati Ph.D. | Senior Vice President of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 15, 2023 | CT ORDER | Filing |
| Jun 5, 2023 | DEFM14A | Filing |
| May 26, 2023 | PREM14A | Filing |
| May 26, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 22, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2023 | 10-K | Annual Report |
| Mar 17, 2023 | EFFECT | Notice of Effectiveness |
| Mar 14, 2023 | 15-12G | Securities registration termination |
| Mar 14, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 14, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |